IBC Dates, Deadlines, and Fees
IBC Meeting Dates
The IBC may choose to review any submission at a convened Meeting. These submissions are designated for Full Committee Review (FCR). All new submissions involving recombinant nucleic acid molecules are designated for FCR. Non-recombinant submissions of increased complexity and concern have a higher likelihood of being designated for FCR.
When to Submit
Protocols must undergo a pre-review procedure that includes an assessment for completeness and confirmation of content prior to being sent to the Committee for review. It is recommended that complex protocols such as those describing multiple aims, RG-2 vectors, pathogenic agents, or novel procedures and technology be submitted at least 4 weeks prior to the meeting. Researchers are encouraged to consider splitting complex projects especially those with multiple aims into additional protocol(s) when possible, to facilitate a faster review process. Protocols that have not sufficiently advanced in the review process may be withheld from the agenda until it has advanced in review process. If you have funding pending IBC approval, please contact the IBC. RSC personnel will work with you to help facilitate the protocol submission, review and approval process.
Scheduled IBC Meeting Dates
|2021 Scheduled IBC Meeting Dates||2022 Scheduled IBC Meeting Dates|
|July 27, 2021||January 25, 2022|
|No meeting in August||No meeting in February|
|September 7, 2021||March 8, 2022|
|October 12, 2021||April 12, 2022|
|November 9, 2021||May 10, 2022|
|December 7, 2021||June 14, 2022|
|July 26, 2022|
|No meeting in August|
|September 13, 2022|
|October 11, 2022|
|November 8, 2022|
|December 13, 2022|
At the discretion of the IBC, scheduled meeting dates may change or additional meeting dates may be added to the schedule.
Fees are assessed in the following situations:
- Industry sponsored clinical trials submitted for review and approval by the IBC.
- Research involving recombinant nucleic acid molecules, hazardous materials, infectious agents, or toxins conducted in UT facilities on behalf of non-UT institutions when there is no award to UT.
|Initial Convened IBC Review||$2,500|
|Tri-Annual Renewal Review||$2,500|